Recommendation ID
HST8/3
Question

Evidence on the progression of X-linked hypophosphataemia (XLH) over time and the long-term benefits of burosumab would also be valuable.

Any explanatory notes
(if applicable)

None


Source guidance details

Comes from guidance
Burosumab for treating X-linked hypophosphataemia in children and young people
Number
HST8
Date issued
October 2018

Other details

Is this a recommendation for the use of a technology only in the context of research? No  
Is it a recommendation that suggests collection of data or the establishment of a register?   No  
Last Reviewed 31/10/2018